SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 51.54-1.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: fred hayes who wrote (11854)6/1/2004 12:28:09 PM
From: rkrw  Read Replies (1) of 52153
 
<<Any thoughts of risk/reward at the new price level?>>

I told myself I'd buy into pozen if 100 was rejected b/c of the potential of 400. The cc was very bad and I'm wondering if there's any fda implications for MT 400. pozen doesn't seem to know. So still sitting on the sidelines.

pozn by attrition becoming a one product company. MT 100 is doa imo. 300 I have no idea. FDA raising the bar and cautious on migraine combo's? Doesn't bode well for pozen and makes it more difficult to bet on a clean MT 400 path to approval.

Seems like the fda concerns were with metoclopramide and not naproxen, so it may well not impact MT 400. All that said, the risk reward is huge. I dunno 3 year hold, $30+ upside with MT 400 a success, $2 downside if not?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News